374 related articles for article (PubMed ID: 24950363)
1. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.
Ku Z; Liu Q; Ye X; Cai Y; Wang X; Shi J; Li D; Jin X; An W; Huang Z
Vaccine; 2014 Jul; 32(34):4296-303. PubMed ID: 24950363
[TBL] [Abstract][Full Text] [Related]
2. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice.
Zhao H; Li HY; Han JF; Deng YQ; Li YX; Zhu SY; He YL; Qin ED; Chen R; Qin CF
Appl Microbiol Biotechnol; 2013 Dec; 97(24):10445-52. PubMed ID: 24085395
[TBL] [Abstract][Full Text] [Related]
3. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge.
Liu Q; Yan K; Feng Y; Huang X; Ku Z; Cai Y; Liu F; Shi J; Huang Z
Vaccine; 2012 Oct; 30(47):6642-8. PubMed ID: 22959985
[TBL] [Abstract][Full Text] [Related]
4. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge.
Chung YC; Ho MS; Wu JC; Chen WJ; Huang JH; Chou ST; Hu YC
Vaccine; 2008 Mar; 26(15):1855-62. PubMed ID: 18329759
[TBL] [Abstract][Full Text] [Related]
5. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection.
Cai Y; Liu Q; Huang X; Li D; Ku Z; Zhang Y; Huang Z
Vaccine; 2013 Apr; 31(18):2215-21. PubMed ID: 23499596
[TBL] [Abstract][Full Text] [Related]
6. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
[TBL] [Abstract][Full Text] [Related]
7. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice.
Wu TC; Wang YF; Lee YP; Wang JR; Liu CC; Wang SM; Lei HY; Su IJ; Yu CK
J Virol; 2007 Oct; 81(19):10310-5. PubMed ID: 17626076
[TBL] [Abstract][Full Text] [Related]
8. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice.
Li HY; Han JF; Qin CF; Chen R
Vaccine; 2013 Jul; 31(32):3281-7. PubMed ID: 23726823
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps.
Ku Z; Ye X; Huang X; Cai Y; Liu Q; Li Y; Su Z; Huang Z
PLoS One; 2013; 8(2):e57601. PubMed ID: 23451250
[TBL] [Abstract][Full Text] [Related]
10. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16.
Shi J; Huang X; Liu Q; Huang Z
Vaccine; 2013 Apr; 31(17):2130-6. PubMed ID: 23499595
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease.
Liu D; Leung K; Jit M; Yu H; Yang J; Liao Q; Liu F; Zheng Y; Wu JT
Clin Microbiol Infect; 2020 Mar; 26(3):373-380. PubMed ID: 31279839
[TBL] [Abstract][Full Text] [Related]
12. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants.
Mao QY; Liao XY; Yu X; Li N; Zhu FC; Zeng Y; Liang ZL; Li FX; Wang JZ; Lu FM; Zhuang H
Chin Med J (Engl); 2010 Jul; 123(13):1679-84. PubMed ID: 20819628
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
14. Combined peptides of human enterovirus 71 protect against virus infection in mice.
Liu JN; Wang W; Duo JY; Hao Y; Ma CM; Li WB; Lin SZ; Gao XZ; Liu XL; Xu YF; Xu WB; Qin C; Zhang LF
Vaccine; 2010 Oct; 28(46):7444-51. PubMed ID: 20831911
[TBL] [Abstract][Full Text] [Related]
15. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses.
Zhao M; Bai Y; Liu W; Xiao X; Huang Y; Cen S; Chan PK; Sun X; Sheng W; Zeng Y
BMC Microbiol; 2013 Dec; 13():287. PubMed ID: 24320792
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
17. Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany.
Rabenau HF; Richter M; Doerr HW
Med Microbiol Immunol; 2010 Feb; 199(1):45-51. PubMed ID: 19941005
[TBL] [Abstract][Full Text] [Related]
18. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide.
Foo DG; Alonso S; Chow VT; Poh CL
Microbes Infect; 2007 Sep; 9(11):1299-306. PubMed ID: 17890123
[TBL] [Abstract][Full Text] [Related]
19. Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant Newcastle disease virus capsids displaying the EV71 VP1 fragment.
Ch'ng WC; Stanbridge EJ; Ong KC; Wong KT; Yusoff K; Shafee N
J Med Virol; 2011 Oct; 83(10):1783-91. PubMed ID: 21837796
[TBL] [Abstract][Full Text] [Related]
20. Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice.
Kolpe AB; Kiener TK; Grotenbreg GM; Kwang J
Virus Res; 2012 Sep; 168(1-2):64-72. PubMed ID: 22728446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
